| Patents for C12N 5 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor (182,629) |
|---|
| 01/29/2003 | EP1278767A1 Albumin fusion proteins |
| 01/29/2003 | EP1278766A2 Polynucleotides for diagnosing mammary gland cancer |
| 01/29/2003 | EP1278544A2 Albumin fusion proteins |
| 01/29/2003 | EP1278537A2 Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis |
| 01/29/2003 | EP1278534A1 Methods and compositions for impairing multiplication of hiv-1 |
| 01/29/2003 | EP1278529A2 Therapeutic uses for mesenchymal stromal cells |
| 01/29/2003 | EP0961824A4 Method of activating dendritic cells |
| 01/29/2003 | EP0863776B1 A biologic material comprising an efficient culture of bone marrow stem cells partially or completely differentiated into connective tissue cells and a three-dimensional biocompatible and biodegradable matrix consisting of a hyaluronic acid derivative |
| 01/29/2003 | EP0858465B1 Anti-tumoral protein |
| 01/29/2003 | EP0610444B1 Use of a polyhydroxybenzamide or a derivative thereof in the manufacture of a medicament for treating viral infectious diseases |
| 01/29/2003 | CN1393556A Active recombination D-glycolylurea |
| 01/29/2003 | CN1393472A Polypeptide-Sec24 protein-31.35 and polynucleotide for coding it |
| 01/29/2003 | CN1100145C Bioactivity protective agent and its use |
| 01/29/2003 | CN1100144C Method for culturing fibrous root of tobacco to prepare nicotin |
| 01/29/2003 | CA2417579A1 Method of proliferating natural killer cells |
| 01/28/2003 | WO2002010356A2 Novel amylolytic enzyme extracted from bacillus sp. a 7-7 (dsm 12368) and washing and cleaning agents containing this novel amylolytic enzyme |
| 01/28/2003 | US6512163 RANK1, an ankyrin-repeat containing peptide from rice associated with disease resistance |
| 01/28/2003 | US6512103 Mammalian chemokine reagents |
| 01/28/2003 | US6512096 Prostate cell surface antigen-specific antibodies |
| 01/28/2003 | US6511848 Propagating preferential blood cells; obtain blood cells, incubate with interleukins, culture, harvest blood cells |
| 01/28/2003 | US6511847 Recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect in the transfected cells; tumor suppressor gene |
| 01/28/2003 | US6511829 Combine the inherent strong visible fluorescent properties of GFPs with the anionic phospholipid binding specificity of annexins; selectively labeling apoptotic cells |
| 01/28/2003 | US6511827 Nucleotide encoding human galanin receptor 3 (GALR3) |
| 01/28/2003 | US6511825 Cell signaling polypeptides and nucleic acids |
| 01/28/2003 | US6511818 Using checkpoint gene-defective (genes that regulate mitosis) cells; potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell |
| 01/28/2003 | US6511811 Protein kinase C antagonist related to insulin receptor |
| 01/28/2003 | US6511807 Carbohydrate ligand that specifically binds to a leczyme; nucleic acid sequence encoding a nonclassical MHC class I heavy chain; ability to associate with a beta 2 microglobulin; major histocompatibility complex transplantation molecules |
| 01/28/2003 | US6511799 Increased expression of CDX2 gene product indicates candidate drug for cancers with mutant adenomatous polyposis coli alleles; catenin/TCF regulated transcription (CRT) is absent in RKO colorectal cancer cell line; CDX2 mRNA and CDX2 protein |
| 01/28/2003 | US6511798 Methods for the preparation of cell monolayers |
| 01/28/2003 | US6511650 Preparing porous hydrogel products |
| 01/28/2003 | US6511473 Implantable bioartificial active secretion system |
| 01/28/2003 | CA2417547A1 Novel amylolytic enzyme extracted from bacillus sp. a 7-7 (dsm 12368) and washing and cleaning agents containing this novel amylolytic enzyme |
| 01/27/2003 | WO2002009745A1 Medicament for the immunotherapy of malignant tumours |
| 01/27/2003 | CA2417374A1 Medicament for the immunotherapy of malignant tumours |
| 01/26/2003 | CA2353804A1 Control of myogenesis by modulation of wnt activity |
| 01/24/2003 | WO2002008456A2 Method for identifying metastatic tumor cells |
| 01/24/2003 | CA2416697A1 Method for identifying metastasizing tumor cells |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006988A1 Cardiovascular safety assay |
| 01/23/2003 | WO2003006950A2 Cells of the cardiomyocyte lineage produced from human pluripotent stem cells |
| 01/23/2003 | WO2003006899A1 Cryopreservation system with controlled dendritic freezing front velocity |
| 01/23/2003 | WO2003006691A1 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| 01/23/2003 | WO2003006661A2 Transgenic plants expressing cobalamin binding proteins |
| 01/23/2003 | WO2003006655A1 Sd1 gene participating in plant semidwarfing and utilization thereof |
| 01/23/2003 | WO2003006651A2 Vascular tissue preferred promoters |
| 01/23/2003 | WO2003006647A1 Allene oxide synthase and divinyl ether synthase from the cyp74-enzyme family isolated out of physcomitrella patens, the nucleotide sequences that code these synthases, and method for producing pathogen-resistant plants |
| 01/23/2003 | WO2003006646A1 Regulation of human aminopeptidase n |
| 01/23/2003 | WO2003006645A2 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | WO2003006638A1 Liver cell progenitor and use for treatment of live diseases |
| 01/23/2003 | WO2003006637A1 Leukocyte preparation |
| 01/23/2003 | WO2003006636A1 Reduction of the stimulatory capacity of antigen-presenting cells |
| 01/23/2003 | WO2003006634A2 Use of oxidised lipoproteins for differentiation of precursor cells into mature dendritic cells |
| 01/23/2003 | WO2003006633A1 Disposable vessel |
| 01/23/2003 | WO2003006632A2 Methods and compisitions for activation human t cells in vitro |
| 01/23/2003 | WO2003006631A1 Leguminous bacterium having potentiated nitrogen fixation ability |
| 01/23/2003 | WO2003006616A2 Pseudotyped adeno-associated viruses and uses thereof |
| 01/23/2003 | WO2003006613A2 Methods for ex vivo propagation of somatic stem cells |
| 01/23/2003 | WO2003006612A2 Production of transduced hematopoietic progenitor cells |
| 01/23/2003 | WO2003006609A2 Human cytokine receptor |
| 01/23/2003 | WO2003006607A2 Inhibition of apoptosis process and improvement of cell performance |
| 01/23/2003 | WO2003006602A2 Subtilase variants |
| 01/23/2003 | WO2003006506A2 Protease inhibitor conjugates and antibodies useful in immunoassay |
| 01/23/2003 | WO2003006504A2 Allelic variants of gpr50 |
| 01/23/2003 | WO2003006499A2 Survivin interacting protein tpr1 |
| 01/23/2003 | WO2003006493A2 Histidine phosphatase interacting protein with 180kd |
| 01/23/2003 | WO2003006492A2 Biologically active peptides |
| 01/23/2003 | WO2003006477A1 IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| 01/23/2003 | WO2003006104A2 Lymphatic endothelial cells materials and methods |
| 01/23/2003 | WO2003006055A2 Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit |
| 01/23/2003 | WO2003005964A2 Recombinant vsv for the treatment of tumor cells |
| 01/23/2003 | WO2003005953A2 Viral proteins capable of binding lar |
| 01/23/2003 | WO2002066509A3 Treatment involving dkk-1 or antagonists thereof |
| 01/23/2003 | WO2002064740A9 Cone snail peptides |
| 01/23/2003 | WO2002061424A3 Organ system microarrays |
| 01/23/2003 | WO2002053711A3 Use of transcription factor yb-1 in adenoviral systems |
| 01/23/2003 | WO2002036790A3 Influenza virus vector for infection of dendritic cells |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002033095A3 Regulation of human serine-threonine protein kinase |
| 01/23/2003 | WO2002029059A3 Nogo receptor homologs |
| 01/23/2003 | WO2002020619A3 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 01/23/2003 | WO2002020569A3 Mammalian genes; related reagents and methods |
| 01/23/2003 | WO2002018585A3 Packaging of positive-strand rna virus replicon particles |
| 01/23/2003 | WO2002016583A3 Constructs and their use in metabolic pathway engineering |
| 01/23/2003 | WO2002014523A3 Methods for stable transformation of plants |
| 01/23/2003 | WO2002012272A3 Therapeutic anti-melanoma compounds |
| 01/23/2003 | WO2002010405A3 A human disintegrin protein |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2002008293A3 Multivalent target binding protein |
| 01/23/2003 | WO2002004022A9 High fidelity polymerases and uses thereof |
| 01/23/2003 | WO2002000904A3 Recombinant constructs and their use in reducing gene expression |
| 01/23/2003 | WO2001090358A3 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | WO2001090337A3 Detection of rna |
| 01/23/2003 | WO2001090333A3 Recombinant bacterial phytases and uses thereof |
| 01/23/2003 | WO2001089364A3 Hcv variants |
| 01/23/2003 | WO2001083782A3 Novel proteases |
| 01/23/2003 | WO2001072768A3 Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
| 01/23/2003 | WO2001066568A3 Use of recombinant antigens to determine the immune status of an animal |
| 01/23/2003 | US20030018997 Nucleotide sequences for use in reducing nicotine concentration in tobacco |
| 01/23/2003 | US20030018984 IGF-I expression system and methods of use |
| 01/23/2003 | US20030018181 Antiinflammatory agents; culturing; isolation of fusion protein |